Fractional CMO for Healthtech
Healthcare technology companies face a go-to-market problem that generic growth playbooks do not solve: your buyer is a clinical or procurement committee, not a growth-hacked SaaS user. The compliance constraints are real. The sales cycle is long. The trust bar is higher than in any other vertical. I have been inside that environment and I know what growth looks like when the product touches patient data.
Israel healthtech: why I understand this market from the inside
Israel produces more healthtech companies per capita than almost any other country. I grew up watching that ecosystem develop, and I have been inside the growth challenges of Israeli technology companies trying to sell into US and European healthcare systems.
The Israeli healthtech advantage is well-documented: deep medical AI capability, a culture of clinical-engineering collaboration coming out of IDF medical units and elite research hospitals like Sheba and Ichilov, and a startup ecosystem that produces clinical-grade products at speed. The go-to-market disadvantage is equally real: selling into US hospital systems or European health ministries from Tel Aviv requires a very different motion than selling into any other enterprise vertical.
I bring the home-field advantage of understanding both sides of that gap. I know what the product teams have built and why it is clinically valuable. I know what the US hospital CIO or the NHS procurement lead needs to see before they will move a deal forward. Bridging that gap is the growth problem I am wired to solve.
Beyond Israel, I work with healthtech companies globally: digital health startups in the US, medtech scale-ups in Germany, telehealth platforms across EMEA. The clinical buyer dynamic is similar across markets. The compliance constraints vary. I have worked inside both.
Clinical and regulatory stakeholders: the CISO-equivalent problem in healthtech
The multi-stakeholder buy
Healthtech deals involve clinical leadership, IT security (HIPAA/GDPR compliance is a gate, not a feature), procurement, and often a medical director or CMO who has veto power on anything touching clinical workflow. Generic demand generation that gets a VP of Digital Health excited does not close a deal when the CISO has not signed off on your data architecture and the clinical committee has not reviewed the evidence base.
Go-to-market strategy for healthtech has to address every node in that buying committee. I build content, case studies, and sales enablement that maps to each stakeholder's specific objection - not a single message broadcast to “health system decision makers.”
Compliant demand generation
HIPAA, GDPR, MDR, FDA 510(k) contexts - each imposes real constraints on what you can claim, how you can use customer data for targeting, and what “evidence” means in a go-to-market context. I have worked with companies where standard retargeting was off the table because of patient data concerns, where email sequences required legal review at every step, and where “case study” meant a peer-reviewed abstract rather than a customer logo and a quote.
Compliant growth is not slow growth. It requires building authority differently: published clinical outcomes, third-party validation, conference presence at HIMSS or Arab Health, and a content strategy that positions the company as a clinical authority rather than a technology vendor. That motion, done right, produces more durable pipeline than any paid acquisition playbook.
The evidence-first go-to-market
Healthcare buyers do not move on hype. They move on proof. That means the growth strategy has to be built backward from the clinical evidence: what outcomes does the product produce, how are those outcomes measured, and how does that evidence get in front of the right committee at the right moment in their buying process?
I build that architecture. It is slower to set up than a paid channel and faster to scale once it is working, because clinical validation compounds. A hospital system that sees your product cited in three peer-reviewed papers is significantly easier to convert than one that has seen your LinkedIn retargeting ads. That is the compounding effect the evidence-first motion produces.
Attribution in long-cycle B2B
Healthtech deals close in 6-24 months. Standard attribution models break on that timeline. I build multi-touch attribution that accounts for the full cycle: first content touch, event interaction, sales development outreach, demo, procurement review, legal, pilot, and close. Without that model, every marketing decision is made on false signals.
See the full engagement models and pricing for how I structure a fractional engagement for long-cycle B2B.
The healthtech companies I work with
Strong fit
Digital health platforms selling into US or European hospital systems. Medical AI companies with clinical evidence that is not being communicated effectively. Israeli healthtech companies building their first US or EU go-to-market. Telehealth and remote patient monitoring companies with a proven clinical product and a broken or absent demand generation motion. Series A to Series C - past proof of concept, needing to build scalable pipeline.
Not the right fit
Consumer health apps where growth is primarily a product and retention problem rather than a B2B sales motion. Companies at pre-clinical stage where the go-to-market is 18+ months away. Medical devices requiring primary FDA regulatory strategy - that is a regulatory affairs problem, not a growth problem, and I am not a regulatory consultant. Pure provider-facing EMR/EHR integrations with procurement cycles that are entirely relationship and channel-partner driven.
Not sure if your stage and model fit? Book the 15-minute scoping call. I will tell you directly.
Fractional CMO for healthtech: common questions
Do you have clinical domain expertise?
I am a growth operator, not a clinician. My expertise is in building go-to-market systems that work inside regulated environments and for clinical buyers. I understand the compliance constraints, the buying committee dynamics, and the evidence standards healthtech buyers apply. I work with clinical advisors and medical affairs teams to make sure the product claims are accurate. I own the go-to-market architecture and the revenue outcome.
How do you handle HIPAA compliance in marketing?
HIPAA applies to Protected Health Information in marketing contexts, primarily around retargeting and CRM practices. I build demand generation programs that do not require PHI: intent-based B2B targeting, content syndication, event-driven pipeline, and ABM programs that target health system accounts without relying on patient-level data. I have worked with legal counsel on compliant email programs, cookie policies for health system visitors, and BAA requirements for marketing technology vendors.
What does a fractional CMO engagement look like for a healthtech company?
It starts with a Diagnostic: 30 days, full funnel audit, assessment of your current demand generation, pipeline attribution, and content/evidence positioning. The output is a prioritized revenue plan. Most healthtech engagements then move to the Operator model: I own the full funnel, direct the content and demand generation programs, build the sales enablement for the buying committee, and hold the attribution model that ties marketing activity to pipeline and closed revenue. See the full breakdown at the engagement models page.
Do you work with Israeli healthtech companies expanding internationally?
Yes, this is a specific competence. The Israeli healthtech export challenge is well-defined: strong clinical evidence, limited brand presence in target markets, a sales motion that relies heavily on personal networks rather than systematic demand generation. I have helped Israeli technology companies build the credibility infrastructure - case studies, thought leadership, conference presence, analyst relations - that US and European health system buyers need before they will engage. The Diagnostic engagement is designed to show you exactly where your international go-to-market is breaking.
Book a 15-minute scoping call
Tell me where your healthtech go-to-market is stuck. I will tell you whether a fractional CMO engagement makes sense and what the first 30 days look like. No pitch. Direct conversation about your pipeline problem.
Sources: Spencer Stuart CMO research · Yaniv Goldenberg on LinkedIn